6.75
+0.365(+5.72%)
Currency In USD
| Previous Close | 6.38 |
| Open | 6.59 |
| Day High | 6.81 |
| Day Low | 6.44 |
| 52-Week High | 11.52 |
| 52-Week Low | 4.44 |
| Volume | 128,418 |
| Average Volume | 97,287 |
| Market Cap | 172.73M |
| PE | -4.92 |
| EPS | -1.37 |
| Moving Average 50 Days | 6.1 |
| Moving Average 200 Days | 7.55 |
| Change | 0.37 |
If you invested $1000 in Nuvectis Pharma, Inc. (NVCT) since IPO date, it would be worth $2,075.38 as of December 05, 2025 at a share price of $6.745. Whereas If you bought $1000 worth of Nuvectis Pharma, Inc. (NVCT) shares 2 years ago, it would be worth $802.02 as of December 05, 2025 at a share price of $6.745.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
Event scheduled for Tuesday, December 2nd at 8:00 AM ETFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precisio
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
GlobeNewswire Inc.
Nov 04, 2025 12:30 PM GMT
NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
Fort Lee, NJ, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical n